Jazz Pharmaceuticals plc (JAZZ) Share buybacks
- Total buybacks · last 12 months (USD): Value $23.00K; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..
Share buybacks
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $23.00K | Trailing-year cash paid for share repurchases. Period ending 2026-06-30. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 23.00K USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-06-30 | $23.00K | (m) | (m) |
| 2025-12-31 | $125.02M | (m) | (m) |
| 2025-09-30 | $125.02M | (m) | (m) |
| 2025-06-30 | $275.02M | (m) | (m) |
| 2024-12-31 | $311.43M | (m) | (m) |
| 2024-09-30 | $411.22M | (m) | (m) |
| 2024-06-30 | $335.59M | (m) | (m) |
| 2023-12-31 | $269.76M | (m) | (m) |
| 2023-09-30 | $169.97M | (m) | (m) |
| 2023-06-30 | $95.59M | (m) | (m) |
| 2022-12-31 | $54.00K | (m) | (m) |
| 2022-09-30 | $54.00K | (m) | (m) |
| 2022-06-30 | $54.00K | (m) | (m) |
| 2021-12-31 | $0.00 | (m) | (m) |
| 2021-09-30 | $0.00 | (m) | (m) |
| 2021-06-30 | $0.00 | (m) | (m) |
| 2021-03-31 | $7.48M | (m) | (m) |
| 2020-12-31 | $146.54M | (m) | (m) |
| 2020-09-30 | $256.87M | (m) | (m) |
| 2020-06-30 | $276.87M | (m) | (m) |
| 2020-03-31 | $329.25M | (m) | (m) |
| 2019-12-31 | $301.45M | (m) | (m) |
| 2019-09-30 | $637.77M | (m) | (m) |
| 2019-06-30 | $639.23M | (m) | (m) |
| 2019-03-31 | $600.38M | (m) | (m) |
| 2018-12-31 | $523.67M | (m) | (m) |
| 2018-09-30 | $119.39M | (m) | (m) |
| 2018-06-30 | $123.50M | (m) | (m) |
| 2018-03-31 | $119.45M | (m) | (m) |
| 2017-12-31 | $98.80M | (m) | (m) |
| 2017-09-30 | $74.90M | (m) | (m) |
| 2017-06-30 | $145.91M | (m) | (m) |
| 2017-03-31 | $157.83M | (m) | (m) |
| 2016-12-31 | $278.30M | (m) | (m) |
| 2016-09-30 | $300.07M | (m) | (m) |
| 2016-06-30 | $213.11M | (m) | (m) |
| 2016-03-31 | $185.58M | (m) | (m) |
| 2015-12-31 | $61.55M | (m) | (m) |
| 2015-09-30 | $33.54M | (m) | (m) |
| 2015-06-30 | $30.42M | (m) | (m) |
| 2015-03-31 | $52.55M | (m) | (m) |
| 2014-12-31 | $42.22M | (m) | (m) |
| 2014-09-30 | $64.06M | (m) | (m) |
| 2014-06-30 | $106.39M | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) |
| 2013-12-31 | $136.48M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) |
| 2012-12-31 | $0.00 | (m) | (m) |
| 2011-12-31 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |